Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B‐cell lymphoma

BACKGROUND: Autoimmune conditions in B‐cell lymphomas are frequent. Steroids are standard of care, but many patients require other immunosuppressive agents. Ibrutinib is a Bruton Tyrosine Kinase inhibitor that is approved for B‐cell indolent lymphoma treatment. We evaluated the use of ibrutinib in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniel, Adrien, Ghez, David, Ravaiau, Camille, Cavalieri, Doriane, Tournilhac, Olivier, Herbaux, Charles, Roriz, Mélanie, Wemeau, Mathieu, Guillet, Stéphanie, Bossard, Jean Baptiste, Hélène, Demarquette, Kaphan, Eleonore, Caroline, Regny, Florence, Lachenal, Pierache, Adeline, Michel, Marc, Godeau, Bertrand, Terriou, Louis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826375/
https://www.ncbi.nlm.nih.gov/pubmed/36048142
http://dx.doi.org/10.1111/ejh.13858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826375/
https://www.ncbi.nlm.nih.gov/pubmed/36048142
http://dx.doi.org/10.1111/ejh.13858

Ejemplares similares